Early Warning for Breast Cancer Metastasis: Molecular Clues from Limitations of Traditional Tests and New Possibilities Breast cancer is the most common cancer among women worldwide, accounting for over one-third of new female cancer cases. Despite advances in treatment, around 20% of early-stage patients still experience metastasis. Traditional markers like CA15-3 and CEA lack sensitivity…

Early Detection of Pancreatic Cancer: Unlocking the Power of ZFP30 and ZNF781 Methylation Markers Gaps and Limitations in Pancreatic Cancer Diagnosis Pancreatic cancer is notoriously difficult to detect early, with most cases diagnosed at an advanced stage. Common tumor markers like CA19-9 and CEA often lack the sensitivity and specificity needed to guide timely treatment decisions. Research Advances In…

EG BioMed was honored to sponsor and participate in PurpleStride 2025, hosted by the Pancreatic Cancer Action Network (PanCAN) on April 26, 2025. The event served as a powerful platform to raise awareness about pancreatic cancer and promote innovation in early detection. The event gathered pancreatic cancer patients, families, clinicians, researchers, and supporters from across…